Clinical trials: CIN3
Cervical Intraepithelial Neoplasia
Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit
1. Implement a single-visit program (SVP) for cervix cancer prevention in clinics serving a multi-ethnic population of women; 2.
- Trial name
- NCT00237562
- Testing
- Large loop electrosurgical excision
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Irvine
Cervical Cancer, CIN2
Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa
The purpose of this study explores the usefulness of urine samples for cervical cancer screening in human immunodeficiency virus (HIV)-infected women.
- Conditions
- Cervical Cancer, CIN2, CIN3
- Trial name
- NCT05413798
- Testing
- Urine HPV testing, Self-collected cervicovaginal specimen, Provider-collected cervical samples
- Where
- South Africa
- Volunteers
- 300 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Cancer, Precancerous Condition
Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection
Precancerous lesions of the cervix occur frequently and are treatable. This justifies a population-based screening program. Following an abnormal Pap smear, patients are referred for a colposcopic exam to confirm the…
- Trial name
- MDC_Algo (NCT01094132)
- Testing
- Multispectral Digital Colposcope (MDC)
- Where
- 3 sites in United States, Canada
- Volunteers
- 551 people
- Sponsor
- British Columbia Cancer Agency
Cervical Cancer, Precancerous Condition
Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia
RATIONALE: Vaccines made from DNA or a gene-modified virus may help the body build an effective immune response to kill tumor cells.
- Conditions
- Cervical Cancer, Precancerous Condition, HPV Disease, Human Papilomavirus
- Trial name
- NCT00788164
- Testing
- TA-HPV, pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine, imiquimod
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Intraepithelial Neoplasia, Papillomavirus Infections
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are precancerous conditions that require effective intervention.
- Trial name
- Aurora (NCT07669363)
- Testing
- Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), HAL 5% with illumination
- Where
- 28 sites in China
- Volunteers
- 230 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cervical Intraepithelial Neoplasia III
Treatment of Cervical Intraepithelial Neoplasia (CIN) Grade III With Non-invasive Physical Plasma
The aim of the prospective, unicenter proof-of-principle study is to investigate the anti-neoplastic effectiveness of NIPP against CIN III lesions.
- Trial name
- ZGynO_CINIII (NCT04753073)
- Testing
- Non-invasive physical plasma
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- University Hospital Tuebingen
Cervical Intraepithelial Neoplasia Grade 3
Exploratory Study of the Efficacy of HAL-PDT in CIN 3
This is a prospective, multicenter, biomarker-guided Phase II study evaluating the efficacy and safety of hexaminolevulinate-mediated cervical photodynamic therapy (HAL-PDT) in women with cervical intraepithelial neoplasia grade…
- Trial name
- Lumiteg-I (NCT07891338)
- Testing
- Hexaminolevulinate (HAL)
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Tongji Hospital
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- NCT03721978
- Testing
- VGX-3100, CELLECTRA™-5PSP
- Where
- 53 sites in United States, Argentina and 8 more
- Volunteers
- 203 people
- Sponsor
- Inovio Pharmaceuticals
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Precancerous Condition
Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171
RATIONALE: Studying Pap smears in the laboratory from women with atypical glandular cells of unspecified significance may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898144
- Testing
- Papanicolaou test, laboratory biomarker analysis
- Volunteers
- 55 people
- Sponsor
- Gynecologic Oncology Group
Human Papillomavirus, CIN 2
Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women
The natural history of human papillomavirus (HPV) is most likely influenced by both innate and adaptive mucosal immunity. More specifically, we hypothesize that Toll like receptors (TLR) play an important role in cervical innate…
- Conditions
- Human Papillomavirus, CIN 2, CIN 3
- Trial name
- NCT01366742
- Where
- 2 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HPV Infections, Cervical Cancer
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT04895020
- Testing
- 9-valent HPV vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Stage 0 Cervical Cancer, High-grade Squamous Intraepithelial Lesion
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Celecoxib may be effective in preventing cervical cancer.
- Trial name
- NCT00072540
- Testing
- celecoxib, anti-cytokine therapy, antiangiogenesis therapy
- Sponsor
- SWOG Cancer Research Network
Cervical Cancer, Diarrhea
Low-Residue Diet in Treating Diarrhea in Patients Receiving Pelvic Radiation Therapy.
RATIONALE: Eating a diet low in residue (fiber, fat, and certain milk or vegetable products) may help prevent or reduce diarrhea caused by pelvic radiation therapy.
- Conditions
- Cervical Cancer, Diarrhea, Prostate Cancer, Radiation Toxicity
- Trial name
- NCT00258401
- Testing
- dietary intervention, management of therapy complications, quality-of-life assessment
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Case Comprehensive Cancer Center
Cervical Cancer, Precancerous Condition
Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix
RATIONALE: Studying the genes expressed in samples of tissue from patients with abnormal cells may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00601601
- Volunteers
- 80 people
- Sponsor
- British Columbia Cancer Agency
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Precancerous Condition
Fenretinide in Treating Patients With Cervical Neoplasia
RATIONALE: Chemoprevention uses drugs to try and prevent development of cancer. Fenretinide may be effective in treating cervical neoplasia and preventing cervical cancer.
- Trial name
- NCT00003075
- Testing
- Fenretinide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer, Precancerous Condition
Gene Expression Profiling of Cervical Cancer Progression in Biopsies and Tissue Samples
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- SAGE (NCT00629577)
- Testing
- microarray analysis, flow cytometry, biopsy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Cervical Cancer, Vulvar Cancer
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 4-valent and 9-valent HPV recombinant vaccine in Chinese healthy females 20 to 45 years of age.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04425291
- Testing
- 4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®
- Where
- China
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Ovarian Serous Adenocarcinoma, Undifferentiated Carcinoma of Ovary
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity
This study is a clinical study aiming at establishing immunological assays for the qualitative and quantitative evaluation of WT-1, Survivin and HPV16 E7-specific immune responses in cancer patients.
- Conditions
- Ovarian Serous Adenocarcinoma, Undifferentiated Carcinoma of Ovary, Cervical Cancer, Cervical Intraepithelial Neoplasia, Grade 3
- Trial name
- NCT02016833
- Testing
- Blood Sampling
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- PX Biosolutions